Clinical development leader with over 14 years of experience advancing oncology and hematology programs from early-stage to regulatory approval. Played a pivotal role in the NDA filing and lifecycle management of a BTK inhibitor for hematologic malignancies. Experienced in Phase 1–3 trials, global submissions, regulatory interactions, and data analysis. Strong background in medical strategy, protocol design, and cross-functional leadership in biotech and academic healthcare environments.